MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform

Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million USD ( $30.5 million CAD) for year ended December 31, 2020

Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its annual 2020 financial results for the year ended December 31 2020.

2020 Financial Highlights (in USD)

  • Total assets as of December 31, 2020 were $85.6 million , including $80.1 million in cash
  • Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million for the year ended December 31, 2020 .
  • Net and comprehensive loss of $35.1 million for the year ended December 31, 2020 .

Current Cash Balance
As of March 30, 2021 maintains a current cash balance of $161 million USD ( $203 million CAD) to advance its portfolio and build out it's technology division.

Earnings Call
An earnings call will be held Thursday, April 1, 2021 at 10:00 am ET .  Details are below:
https://mindmed-co.zoom.us/webinar/register/WN_2-RxTijCTzOX2cpuaMrXJw

Complete financial statements along with related management's discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com .

About MindMed
MindMed is a psychedelic medicine biotech company seeking to discover, develop and deploy psychedelic inspired medicines and therapies to address addiction and mental illness. The Company is assembling a drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC.

MindMed trades on the Canadian exchange NEO under the symbol   MMED . MindMed is also traded in the United States under the symbol   MMEDF and in Germany under the symbol   MMQ .

MindMed Forward-Looking Statements
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the heading "Risk Factors" in the Company's annual information form for the year ended December 31, 2020 filed with the securities regulatory authorities in all provinces and territories of Canada and available under the Company's profile on SEDAR at www.sedar.com . Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Media Contact: mindmed@150bond.com

Cision View original content: https://www.prnewswire.com/news-releases/mindmed-announces-2020-year-end-financial-results-current-cash-balance-of-161-million-usd-203-million-cad-to-support-drug-development-pipeline-and-creation-of-psychedelic-medicine-tech-platform-301258180.html

SOURCE Mind Medicine (MindMed) Inc.

Cision View original content: https://www.newswire.ca/en/releases/archive/March2021/30/c5156.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Sort by

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Newly created role of Chief Patient Officer reinforces Compass' vision of working to achieve broad and equitable access to COMP360, if approved

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Newly created role of Chief Patient Officer reinforces Compass' vision of working to achieve broad and equitable access to COMP360, if approved

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways Announces Pricing of Underwritten Offering

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares ("ADSs") and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant ("ADS Warrant") to purchase one ADS, which has an exercise price of $5.796 per ADS, representing a 40% premium to the last sale price and will be exercisable following a specified data milestone. The offering price is $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. All of the securities are to be sold by Compass. The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways Announces Pricing of Underwritten Offering

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares ("ADSs") and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant ("ADS Warrant") to purchase one ADS, which has an exercise price of $5.796 per ADS, representing a 40% premium to the last sale price and will be exercisable following a specified data milestone. The offering price is $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. All of the securities are to be sold by Compass. The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways to Participate in December Investor Conferences

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings:

  • 7 th Annual Evercore ISI HealthCONx Conference: Fireside chat at 10:25am ET on December 3, 2024
  • Piper Sandler 36 th Annual Healthcare Conference: Fireside chat at 3:30pm ET on December 4, 2024

A live audio webcast of these events will be accessible here for 30 days following the events.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×